{"id":169217,"date":"2024-05-06T02:42:40","date_gmt":"2024-05-06T06:42:40","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/tar-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk\/"},"modified":"2024-08-18T11:48:13","modified_gmt":"2024-08-18T15:48:13","slug":"tar-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tar-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk.php","title":{"rendered":"TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk&#8230;"},"content":{"rendered":"<p><![CDATA[Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations1]]><\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/05\/2875486\/0\/en\/TAR-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk-non-muscle-invasive-bladder-cancer-respec.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk...\">TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Link: TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tar-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169217","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169217"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169217"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169217\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}